47 completed, 4 not yet recruiting, 3 unknown, 2 terminated. 58 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 58 | Completed 47, Not yet recruiting 4, Unknown 3, Terminated 2, Recruiting 1, Withdrawn 1 |
| Phase 2 | 8 | Completed 6, Terminated 1, Unknown 1 |
Follow Hyperlipidemia: new trials by email Literature Review of Hyperlipidemia trials Research Report on Hyperlipidemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Study of VELA-101 in Adult Participants VELA-101, Placebo - Healthy Participants, Hyperlipidemia | Phase 1 | Not yet recruiting | Ursa Medicines | 60 | 2026-11-01 | 2026-10-15 |
| A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B Treatment A(AD-236A), Treatment B(AD-236B), Treatment C(AD-236A+AD-236B) - Hyperlipidemia, Diabete Type 2 | Phase 1 | Not yet recruiting | Addpharma Inc. | 44 | 2026-07-29 | 2026-07-28 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAL0167 in Healthy Participants SAL0167 group, SAL0167 placebo group - Hyperlipidemia | Phase 1 | Not yet recruiting | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 120 | 2026-07-21 | 2026-07-23 |
| A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C Treatment A(AD-231A), Treatment B(AD-231B+AD-231C), Treatment C(AD-231A+AD-231B+AD-231C) - Hypertension, Hyperlipidemia | Phase 1 | Not yet recruiting | Addpharma Inc. | 55 | 2026-01-23 | 2025-12-31 |
| A Study to Evaluate COR-1004 in Adult Volunteers. COR-1004, Placebo - Hyperlipidemia | Phase 1 | Recruiting | Corsera Health | 80 | 2025-11-28 | 2026-10-26 |
| A Clinical Trial of HRS-1301 on the Pharmacokinetics of Rosuvastatin Calcium Tablets in Healthy Subjects HRS-1301 Tablets, Rosuvastatin Calcium Tablets - Hyperlipidemia | Phase 1 | Completed | Shandong Suncadia Medicine Co., Ltd. | 16 | 2025-10-09 | 2026-01-09 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-1301 in Healthy Subjects HRS-1301, HRS-1301 placebo - Hyperlipidemia | Phase 1 | Completed | Shandong Suncadia Medicine Co., Ltd. | 84 | 2025-03-18 | 2026-09-30 |
| A Study on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7249 Injection in Healthy Subjects HRS-7249 injection, Placebo - Hyperlipidemia | Phase 1 | Completed | Fujian Shengdi Pharmaceutical Co., Ltd. | 48 | 2024-08-15 | 2025-09-15 |
| A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of JS401 JS401, Placebo - Hyperlipidemia | Phase 1 | Unknown | Shanghai Junshi Bioscience Co., Ltd. | 44 | 2023-08-31 | 2023-09-18 |
| Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-C 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran), Placebo, 300 mg inclisiran sodium (equivalent to 284 mg inclisiran) - Hyperlipidemia | Phase 1 | Completed | Novartis Pharmaceuticals | 40 | 2021-02-26 | 2025-03-25 |
| Study to Evaluate the Effect of Food on the Pharmacokinetics of ASC41 in Healthy Volunteers ASC41 tablet - Healthy, NAFLD | Phase 1 | Completed | Gannex Pharma Co., Ltd. | 12 | 2020-12-27 | 2024-09-27 |
| Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects ASC 41, ASC 41 Placebo - Overweight and Obesity, NAFLD | Phase 1 | Completed | Gannex Pharma Co., Ltd. | 20 | 2020-12-22 | 2024-09-27 |
| Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics of DC371739 Single-Dose Treatment in Healthy Subjects DC371739, Placebo - Hyperlipidemia | Phase 1 | Completed | Guangzhou JOYO Pharma Co., Ltd | 43 | 2020-09-25 | 2025-08-03 |
| The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia SHR-1209, Placebo - Hyperlipidemia | Phase 1 / Phase 2 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 110 | 2019-06-20 | 2022-11-30 |
| Investigate the Effect of Food on the Pharmacokinetics of JLP-1310 in Healthy Male Volunteers JLP-1310, Fasted followed by fed, JLP-1310, Fed followed by fasted - Diabetes, Hyperlipidemia | Phase 1 | Completed | Jeil Pharmaceutical Co., Ltd. | 16 | 2017-08-02 | 2018-03-29 |
| The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers Metformin + Rosuvastatin, JLP-1310 - Diabetes, Hyperlipidemia | Phase 1 | Completed | Jeil Pharmaceutical Co., Ltd. | 40 | 2017-07-06 | 2018-03-29 |
| Clinical Trial to Compare the Safety and Pharmacokinetics of YHP1604 in Comparison to the Co-administration of Telmisartan/Amlodipine and Rosuvastatin Temisartan/Amlodipine+Rosuvastatin, YHP1604 - Hypertension, Hyperlipidemia | Phase 1 | Completed | Yuhan Corporation | 62 | 2017-04-21 | 2019-01-16 |
| Bioequivalence Study of CJ-30061 in Healthy Male Volunteers CJ-30061, Exforge® 5/160mg & Lipitor® 20mg - Hypertension, Hyperlipidemia | Phase 1 | Completed | HK inno.N Corporation | 42 | 2016-09-19 | 2018-09-05 |
| A Study to Investigate Pharmacokinetic Drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin Twynsta 80/5mg, Crestor 20mg - Hypertension, Hyperlipidemia | Phase 1 | Completed | Yuhan Corporation | 60 | 2016-08-01 | 2017-02-01 |
| A Comparison Study to Evaluate the Pharmacokinetics and Safety of NK-104-CR in Healthy Adult Volunteers A: NK-104-CR 8 mg, B: Pitavastatin IR 4 mg, C: Pitavastatin IR 8 mg - Hyperlipidemia | Phase 1 | Completed | Kowa Research Institute, Inc. | 18 | 2015-12-01 | 2016-01-11 |
Showing 20 of 58. Sign in to see all of them.
Hyperlipidemias (58) · Hypertension (17) · Obesity (5) · Diabetes Mellitus (4) · Hypercholesterolemia (3) · Body Weight (2) · Cardiovascular Diseases (2) · Essential Hypertension (2) · HIV Infections (2) · Hyperglycemia (2) · Inflammation (2) · Metabolic Syndrome (2) · Motor Activity (2) · Non-alcoholic Fatty Liver Disease (2) · Overweight (2)
Dyslipidemias (58) · Lipid Metabolism Disorders (58) · Metabolic Diseases (58) · Nutritional and Metabolic Diseases (58) · Vascular Diseases (19) · Cardiovascular Diseases (18) · Glucose Metabolism Disorders (9) · Pathological Conditions, Signs and Symptoms (9) · Signs and Symptoms (7) · Nutrition Disorders (6) · Overnutrition (6) · Body Weight (5) · Endocrine System Diseases (5) · Overweight (4) · Urogenital Diseases (4)
Rosuvastatin Calcium (10) · Atorvastatin (7) · Telmisartan (5) · Amlodipine (4) · Metformin (3) · Valsartan (3) · pitavastatin (3) · telmisartan amlodipine combination (3) · Ezetimibe (2) · Fatty Acids, Omega-3 (2) · evolocumab (2) · fimasartan (2) · levamlodipine (2) · ALN-PCS (1) · Amlodipine, Valsartan Drug Combination (1)
Jeil Pharmaceutical Co., Ltd. (4) · Yuhan Corporation (4) · Chong Kun Dang Pharmaceutical (3) · Addpharma Inc. (2) · Amgen (2) · Boryung Pharmaceutical Co., Ltd (2) · Gannex Pharma Co., Ltd. (2) · JW Pharmaceutical (2) · Kowa Research Institute, Inc. (2) · Organon and Co (2) · Shandong Suncadia Medicine Co., Ltd. (2) · University of Manitoba (2) · Avera McKennan Hospital & University Health Center (1) · Caroline Medical Group (1) · Corsera Health (1)
South Korea (20) · United States (16) · China (10) · Canada (2) · Australia (1) · Cameroon (1) · Japan (1) · New Zealand (1) · United Kingdom (1)
Kyun Seop Bae, MD (2) · Ann Melvin, MD (1) · Charles H Ballow, Pharm D. (1) · Curtis Rempel, PhD, MBA (1) · Donald I Abrams, MD (1) · Dong-seok Yim, professor (1) · Gary D Foster, PhD (1) · Gary Fulcher, PhD (1) · JaeWook Ko, PhD (1) · Judith Aberg, M.D. (1) · Julius E Oben, PhD (1) · Jung-ryul Kim, MD, Ph.D (1) · Kyung-Sang Yu, M.D., Ph.D., M.B.A. (1)
PMID 18068514, PMID 21120461, PMID 21593349, PMID 21831304, PMID 22743313, PMID 23638799, PMID 23706094, PMID 24077434, PMID 25202920, PMID 35039035, PMID 37164838, PMID 40587053
M01RR000334 (1), R21AG023805 (1), R21NR011281 (1), U01AI068632 (1), U54DK083912 (1)